Reuters logo
Myriad Genetics' fourth-quarter profit beats estimates
August 13, 2013 / 8:16 PM / 4 years ago

Myriad Genetics' fourth-quarter profit beats estimates

Aug 13 (Reuters) - Molecular diagnostics company Myriad Genetics Inc reported a fourth-quarter profit that handily beat analysts’ estimates, helped by higher sales of its breast and ovarian cancer detection test.

Net income rose to $44.1 million, or 53 cents per share, from $29.1 million, or 34 cents per share, a year earlier.

Revenue rose 31 percent to $174.1 million in the quarter ended June 30.

Analysts on average expected earnings of 44 cents on revenue of $159.9 million, according to Thomson Reuters I/B/E/S.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below